MicroRNA-133a improves the cardiac function and fibrosis through inhibiting Akt in heart failure rats

Biomedicine and Pharmacotherapy

Volumn 71, Issue , 2015, Pages 185-189

  Sang, Hai Qiang ^a   Jiang, Zheng Ming ^a   Zhao, Qiu Ping ^b   Xin, Fu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Akt; Fibrosis; Heart failure; MiR 133a

Indexed keywords

MICRORNA; MICRORNA 133A; PROTEIN KINASE B; TRICIRIBINE; UNCLASSIFIED DRUG; MIRN133 MICRORNA, HUMAN; MIRN133 MICRORNA, RAT; PROTEIN KINASE INHIBITOR; RIBONUCLEOSIDE;

ANATOMICAL CONCEPTS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE FIBROSIS; HEART WEIGHT; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; HEART FUNCTION TEST; HEMODYNAMICS; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ANIMALS; BODY WEIGHT; CHRONIC DISEASE; FIBROSIS; GENE EXPRESSION REGULATION; HEART FAILURE; HEART FUNCTION TESTS; HEMODYNAMICS; MICRORNAS; ORGAN SIZE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RIBONUCLEOSIDES;

EID: 84928953471     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.02.030     Document Type: Article

References (17)

1. Piepoli M.F., Scott A.C., Capucci A., Coats A.J. Skeletal muscle training in chronic heart failure. Acta Physiol. Scand. 2001, 171:295-303.
2. Hancock H.C., Close H., Fuat A., Murphy J.J., Hungin A.P., Mason J.M. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. BMJ Open 2014, 4:e003866.
3. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
4. Cuellar T.L., McManus M.T. MicroRNAs and endocrine biology. J. Endocrinol. 2005, 187:327-332.
5. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 2010, 11:597-610.
6. Izarra A., Moscoso I., Levent E., Canon S., Cerrada I., Diez-Juan A., et al. miR-133a enhances the protective capacity of cardiac progenitors cells after myocardial infarction. Stem Cell Rep. 2014, 3:1029-1042.
7. Chen S., Puthanveetil P., Feng B., Matkovich S.J., Dorn G.W., Chakrabarti S. Cardiac miR-133a overexpression prevents early cardiac fibrosis in diabetes. J. Cell. Mol. Med. 2014, 18:415-421.
8. Danowski N., Manthey I., Jakob H.G., Siffert W., Peters J., Frey U.H. Decreased expression of miR-133a but not of miR-1 is associated with signs of heart failure in patients undergoing coronary bypass surgery. Cardiology 2013, 125:125-130.
9. Cui W., Zhang S., Shan C., Zhou L., Zhou Z. microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J. 2013, 280:3962-3974.
10. Shi Z., Chen A.D., Xu Y., Chen Q., Gao X.Y., Wang W., et al. Long-term administration of tempol attenuates postinfarct ventricular dysfunction and sympathetic activity in rats. Pflugers Arch. 2009, 458:247-257.
11. Wu Y., Wang Y.Q., Wang B.X. [MicroRNA-133a attenuates isoproterenol-induced neonatal rat cardiomyocyte hypertrophy by downregulating L-type calcium channel alpha1C subunit gene expression]. Zhonghua Xin Xue Guan Bing Za Zhi 2013, 41:507-513.
12. Ye H., Ling S., Castillo A.C., Thomas B., Long B., Qian J., et al. Nebivolol induces distinct changes in profibrosis microRNA expression compared with atenolol, in salt-sensitive hypertensive rats. Hypertension 2013, 61:1008-1013.
13. Eitel I., Adams V., Dieterich P., Fuernau G., de Waha S., Desch S., et al. Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J. 2012, 164:706-714.
14. Bagnall R.D., Tsoutsman T., Shephard R.E., Ritchie W., Semsarian C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One 2012, 7:e44744.
15. Castoldi G., Di Gioia C.R., Bombardi C., Catalucci D., Corradi B., Gualazzi M.G., et al. MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J. Cell. Physiol. 2012, 227:850-856.
16. Dostal D.E., Feng H., Nizamutdinov D., Golden H.B., Afroze S.H., Dostal J.D., et al. Mechanosensing and regulation of cardiac function. J. Clin. Exp. Cardiol. 2014, 5:314.
17. Wende A.R., O'Neill B.T., Bugger H., Riehle C., Tuinei J., Buchanan J., et al. Enhanced cardiac Akt/PKB signaling contributes to pathological cardiac hypertrophy in part by impairing mitochondrial function via transcriptional repression of nuclear-encoded mitochondrial genes. Mol. Cell. Biol. 2014.